Please note: AABB reserves the right to make updates to this program.
Live Program Date: Wednesday, September 12, 2018 -
Master Program Number: 18EL-361 (see program format numbers below under Registration)
Educational Track: Technical/Clinical
Topic: Transfusion Medicine
Intended Audience: Hospital Blood Banks, Immunohematology Reference Labs (IRL’s), Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Physicians, Students (MD, MT, SBB), Technologists
Teaching Level: Intermediate
Director/Moderator: Laura Nelson, MLS(ASCP)SBBcm, Reference Laboratory and Product Management Supervisor, LifeServe Blood Center, Des Moines, IA
Speaker: Chang Liu, MD, PhD, Assistant Professor of Pathology and Immunology, Director of HLA Laboratory, Attending physician in Transfusion Medicine, Washington University School of Medicine/Barnes-Jewish Hospital, St. Louis, MO
After participating in this educational activity, participants should be able to:
- Define nonspecific agglutination and describe its appearance in different methodologies.
- Evaluate the methodologies available to avoid nonspecific agglutination interference in antibody identification.
- Explain nonspecific agglutination to physicians and nurses who do not have a transfusion medicine background.
- Use information from the program in developing and reviewing SOPs in their facility.
The use of more sensitive antibody testing methods such as column agglutination (gel) and solid phase capture have increased the frequency of nonspecific agglutination. When this reactivity is seen, the blood bank has to determine how far to take the identification, what to report in the medical record, and what type of crossmatch to perform if transfusion is needed in these patients. This program will address the issue of nonspecific agglutination in gel and solid phase methodologies. Faculty will discuss the different methods available to avoid the reactivity while still being able to identify clinically significant antibodies and discuss what type of crossmatch to perform if transfusion is needed. Finally, how to report these results in the medical record and explain them to physicians and nurses who do not have a transfusion medicine background will be discussed.
| || ||
|Single Viewer: On-Demand||
|Group Viewing: On-Demand||
Continuing Education Credit
AABB designates both the live and on-demand version of this eCast each eligible for 1 continuing education credit/contact hour for Physicians, General Participation, California Nurse, California Lab Personnel and Florida Lab Personnel. The number and type of credits awarded for this program (both live and on-demand) was determined by the program duration. For more information on each credit type please visit our
Continuing Education Credits webpage.
Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.
Dr. Chang Liu is a Transfusion Medicine physician and Medical Director of the HLA Laboratory at Washington University School of Medicine. He received his MD from Peking Union Medical College and PhD from Oregon Health & Science University. He finished his residency in Clinical Pathology and fellowships in Transfusion Medicine and Histocompatibility at Washington University, where he subsequently joined the faculty as an Assistant Professor of Immunology and Pathology. He published in Transfusion and presented at an AABB Annual Meeting Education program on the topic of antibody of undetermined specificity. His research interests are alloimmunization to red cell antigens and HLA, pretransfusion testing, and transplant diagnostics.